If someone can only look at the issue in such generic terms and comes up with such a deeply flawed analysis that they missperceive one of the most positive events that can happen to a drug candidate at this stage [[the toxicity is SO LOW that preliminary tox tests are required. OH< and BTW: there's a strong possibility that the drug may qualify for a FAST TRACK. And the time to the end of clinical trials will be much FASTER]]
Perhaps some are investing in a sector where their understanding is dangerously inadequate.
BTW: the OTHER major qualification for a fast track (other than very low toxicity) is high efficacy, which NNVC's drug also appears to have "in spades".
PS!!! Also note that getting a "fast track" very greatly speeds up the process of clinical trials IN ADDITION to all the other factors. (shouldn't have to point that out, but considering past posts .....)